Glucagon Peptide Agonists Market Trends: Brand Comparison, Technical Pros & Cons, and Product Selection Guide
Published: July 13, 2026 13:55
Author: Carmen Robinson
Abstract: The glucagon peptide agonists market is expanding rapidly, driven by rising demand in metabolic and obesity therapies. Key brands (e.g., Novo Nordisk, Eli Lilly) compete on efficacy, half-life, and side-effect profiles. Technical pros include high receptor specificity and sustained release; cons involve injection-site reactions and stability challenges. Product selection hinges on purity (>98%), regulatory certifications (FDA, EMA, GMP), and cold-chain logistics. Current trends favor dual/triple agonists (GIP/GLP-1/glucagon) with superior weight loss. Industry data projects a CAGR of 12.5% (2024–2030). This guide compares parameters (purity, bioactivity), brand status, and factory qualifications to optimize procurement.